Evaluate individual patient psychology to better understand the impact of the COVID-19 pandemic on clinical trial data
The impact of the COVID-19 pandemic on ongoing clinical trials is multi-factorial: it is changing the way patients interact with clinical investigators and clinical sites, changing the way outcomes are measured and increasing patient stress. Patients will perceive these factors uniquely and their response will be influenced by individual characteristics including psychology, expectation and social support. COV-IQ provides an additional level of data to better understand patient behavior and response to crisis in clinical trials.
Patient’s crisis response will depend on multiple factors:
- Psychological traits
- Relationship with trial site and staff
- Social factors
Data driven approach
Address data variability
Data can be analyzed using advanced proprietary mathematical and statistical techniques (e.g. machine learning) to potentially improve analysis of clinical trial data and reduce the risk of an inconclusive trial.
Dear partners and friends,
The COVID-19 pandemic is impacting us at the level of countries, communities, companies and families. We all recognize the difficult task of maintaining business continuity in the face of uncertainty, and the potential upheaval caused by the interruption and delay of activities. Yet, as members of the biopharma community, we remain committed to our common mission of delivering medicines to patients. We, as leaders of the industry, have both the opportunity and the obligation to design the future. Meeting the challenges posed to portfolio delivery, timelines and data will require new levels of innovation and cooperation.
Tomorrow even more than today, our corporate values will drive us on the path we have set since the inception of the company. We are emboldened in our commitment to develop methodologies to optimize and de-risk clinical development.
From my team to yours, I wish you and your families good health.